The estimated Net Worth of Muthusamy Shanmugam is at least $75.2 Millón dollars as of 18 July 2024. Muthusamy Shanmugam owns over 2,743 units of ANI Pharmaceuticals Inc stock worth over $34,363,918 and over the last 3 years Muthusamy sold ANIP stock worth over $40,790,467.
Muthusamy has made over 24 trades of the ANI Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Muthusamy sold 2,743 units of ANIP stock worth $170,066 on 18 July 2024.
The largest trade Muthusamy's ever made was selling 50,000 units of ANI Pharmaceuticals Inc stock on 15 December 2023 worth over $2,627,500. On average, Muthusamy trades about 24,971 units every 31 days since 2021. As of 18 July 2024 Muthusamy still owns at least 632,620 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Muthusamy Shanmugam stock trades at the bottom of the page.
Muthusamy's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... y Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: